Highest-materiality recent filing
Bluejay Diagnostics Q1 2026: net loss $1.9M, SYMON-II study at 680 of 750 patients
Cash and equivalents $3.7M as of Mar 31, 2026; net loss $1.9M unchanged YoY.
Bluejay Diagnostics completes 624 of 750 patient enrollments in SYMON-II sepsis trial
SYMON-II pivotal trial for Symphony IL-6 sepsis triage test enrolled 624 of 750 target patients.
Bluejay Diagnostics raises $125,000 in private placement to insiders at $2.00/share
Issued 62,500 shares of common stock at $2.00 per share to five insiders, including CEO Neil Dey and Chair Donald Chase.
Bluejay acknowledges NorthStrive's acquisition suggestion, reiterates focus on Symphony platform
Responds to NorthStrive Fund II LP letter proposing acquisition of Phase-1-ready chronic cough therapeutic program.
Bluejay announces Symphony IL-6 Test abstract accepted for SAEM 2026 meeting
Abstract accepted for presentation at Society of Academic Emergency Medicine Annual Meeting, May 18-21, 2026 in Atlanta.
Bluejay Diagnostics reports FY2025 net loss $6.8M; cash $5.2M; needs >$20M additional capital
Net loss of ~$6.8M for FY2025; cash and cash equivalents $5.2M; stockholders' equity $6.0M as of Dec 31, 2025.
All prefunded warrants from Oct 2025 private placement fully exercised as of Feb 19, 2026.
Bluejay Diagnostics enrolls 545 patients in SYMON™ II study, exceeds expectations
Enrolled 545 of 750 target patients in SYMON™ II multicenter IL-6 monitoring study, exceeding initial expectations.
Bluejay Diagnostics implements 1-for-4 reverse stock split effective Jan 29, 2026
Reverse stock split at 1-for-4 ratio; outstanding shares reduced from ~2,834,133 to ~708,533.
Bluejay Diagnostics completes commercial-scale IL-6 antibody production for Symphony cartridges
Completed commercial-scale production of polyclonal and monoclonal anti-IL-6 antibodies meeting internal performance criteria.
Bluejay Diagnostics Q3 update: SYMON-II 50% enrolled, $3.08M cash, needs $20M more by 2027
Q3 cash $3.08M; stockholders' equity $3.69M. Raised $3.85M in April and $4.5M PIPE in October.
Bluejay Diagnostics raises $4.5M in private placement of stock and warrants
Gross proceeds of $4.5M; net proceeds ~$4.0M after 8% placement agent fee and expenses.
Bluejay expands SanyoSeiko partnership for Symphony platform commercialization
SanyoSeiko will serve as contract manufacturing organization for analyzers, cartridges, and components.
Bluejay Diagnostics announces Board chair and committee chair changes
Donald R. Chase appointed Chairperson of the Board, succeeding Douglas C. Wurth.
Bluejay Diagnostics Q2 update: SYMON-II enrollment starts, 510(k) target 2027
SYMON-II pivotal trial enrollment began; aims to validate IL-6 for 28-day mortality in ICU patients.
Bluejay extends alternative manufacturing deadline by one year, pays $71k for final chip supply
Deadline to establish alternative manufacturing site for Symphony cartridges extended from Oct 2025 to Oct 2026.
Bluejay Diagnostics shareholders approve reverse stock split of up to 1-for-20
Re-elected directors Chase, N. Dey, S. Dey, Wurth, Zeidman to 2026 term.
Bluejay Diagnostics mid-year update: cash $5.7M, headcount cut to 5, seeks $30M+ funding
SYMON-II pivotal sepsis trial enrolling; 510(k) submission planned for Q4 2027, FDA approval target Q3 2028.
CTO Jason Cook's employment ends May 30, 2025 under separation agreement.
Under the terms of the Separation Agreement, Dr. Cook will cease employment with the Company on May 30, 2025.
Max materiality 0.75 · Median 0.55 · Most common event other_material